Latest News and Press Releases
Want to stay updated on the latest news?
-
NESS ZIONA, Israel, Oct. 16, 2019 (GLOBE NEWSWIRE) -- Sol-Gel Technologies, Ltd. (NASDAQ: SLGL) today announced it will present research on the use of its proprietary microencapsulation technology...
-
Top-line generic product revenue of $7.8 millionTWIN Phase 3 trials are fully enrolled and remain on track to report results in 4Q19 NESS ZIONA, Israel, Aug. 13, 2019 (GLOBE NEWSWIRE) -- Sol-Gel...
-
NESS ZIONA, Israel, Aug. 08, 2019 (GLOBE NEWSWIRE) -- Sol-Gel Technologies, Ltd. (Nasdaq: SLGL) (“Sol-Gel” or the “Company”), a clinical-stage dermatology company focused on identifying, developing...
-
Notice of allowance for U.S. patent application extends TWIN patent protection to 2038Clinical study for SGT-210 in palmoplantar keratoderma (PPK) intended to begin in early 2020Webcast of Analyst...
-
All primary and secondary endpoints achieved in both Phase 3 clinical trialsRapid efficacy demonstrated, with statistical significance reached as early as Week 2 compared with vehicleFavorable safety...
-
NESS ZIONA, Israel, June 17, 2019 (GLOBE NEWSWIRE) -- Sol-Gel Technologies, Ltd. (NASDAQ: SLGL) (“Sol-Gel” or the “Company”), a clinical-stage dermatology company focused on identifying, developing...
-
NESS ZIONA, Israel, May 28, 2019 (GLOBE NEWSWIRE) -- Sol-Gel Technologies, Ltd. (NASDAQ: SLGL) (“Sol-Gel” or the “Company”), a clinical-stage dermatology company focused on identifying, developing...
-
NESS ZIONA, Israel, May 23, 2019 (GLOBE NEWSWIRE) -- Sol-Gel Technologies, Ltd. (NASDAQ: SLGL) (“Sol-Gel” or the “Company”), a clinical-stage dermatology company focused on identifying, developing...
-
Top-line results from Phase III Epsolay® and TWIN trials remain on track; mid-2019 and 4Q19, respectfully Reports top-line generic product revenues of $6.3 million NESS ZIONA, Israel, May 22, 2019...
-
NESS ZIONA, Israel, April 18, 2019 (GLOBE NEWSWIRE) -- Sol-Gel Technologies Ltd. (NASDAQ: SLGL) (“Sol-Gel” or the “Company”), a clinical-stage dermatology company focused on identifying, developing...